Gritstone bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Gritstone bioDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 151.3% bzw. 2% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich um 13% pro Jahr wachsen wird.

Wichtige Informationen

-2.0%

Wachstumsrate der Gewinne

13.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	-151.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:2JQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-133	N/A	N/A	1
12/31/2024	3	-115	N/A	N/A	1
6/30/2024	15	-133	-112	-111	N/A
3/31/2024	16	-145	-118	-115	N/A
12/31/2023	16	-138	-126	-122	N/A
9/30/2023	10	-139	-138	-133	N/A
6/30/2023	12	-130	-133	-127	N/A
3/31/2023	15	-125	-128	-123	N/A
12/31/2022	20	-120	-122	-116	N/A
9/30/2022	19	-118	-115	-109	N/A
6/30/2022	18	-116	-105	-98	N/A
3/31/2022	16	-112	-101	-95	N/A
12/31/2021	48	-75	-56	-51	N/A
9/30/2021	46	-72	-57	-52	N/A
6/30/2021	45	-70	-61	-57	N/A
3/31/2021	42	-71	-58	-55	N/A
12/31/2020	4	-105	-93	-89	N/A
9/30/2020	4	-106	-95	-86	N/A
6/30/2020	4	-107	-105	-91	N/A
3/31/2020	4	-103	-104	-89	N/A
12/31/2019	4	-94	-101	-85	N/A
9/30/2019	5	-84	-88	-76	N/A
6/30/2019	4	-75	-56	-49	N/A
3/31/2019	3	-69	-49	-42	N/A
12/31/2018	1	-65	-44	-38	N/A
9/30/2018	0	-65	-46	-40	N/A
6/30/2018	N/A	-56	-60	-49	N/A
3/31/2018	N/A	-47	N/A	-44	N/A
12/31/2017	N/A	-41	N/A	-35	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 2JQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 2JQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 2JQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 2JQDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-151.3% pro Jahr).

Hohe Wachstumseinnahmen: 2JQDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-151.3% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 2JQ in 3 Jahren voraussichtlich hoch sein wird

Gritstone bio Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gritstone bio, Inc. Announces Encouraging Updated Interim Phase 2 Data from Ongoing Phase 2 Study Evaluating GRANITE

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.31 loss in 2Q 2023)

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Full year 2023 earnings released: US$1.20 loss per share (vs US$1.32 loss in FY 2022)

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Third quarter 2023 earnings released: US$0.33 loss per share (vs US$0.35 loss in 3Q 2022)

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2022)

New major risk - Financial position

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.34 loss in 1Q 2022)

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$1.32 loss per share (vs US$0.95 loss in FY 2021)

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in 3Q 2021)

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 2Q 2021)

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.16 profit in 1Q 2021)

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.69 loss in 3Q 2020)

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)

High number of new directors

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Growth Index

First quarter 2021 earnings released: EPS US$0.10 (vs US$0.71 loss in 1Q 2020)

Full year 2020 earnings released: US$2.79 loss per share (vs US$2.81 loss in FY 2019)

Revenue beats expectations

Gritstone Oncology, Inc. Announces Promotions Within its Leadership Team

Gritstone Oncology, Inc Announces Board Appointments

Executive VP & CTO recently sold €182k worth of stock

Gritstone Oncology, Inc. and Genevant Sciences Announce License Agreement for COVID-19 Vaccine

Gritstone Oncology, Inc. Advances Development of Second Generation Vaccine Against SARS-CoV-2

Gritstone Oncology, Inc. announced that it expects to receive $15.000001 million in funding

New 90-day high: €3.34

Gritstone Oncology, Inc. announced that it expects to receive $110 million in funding from Avidity Partners Management LP, EcoR1 Capital, LLC, Redmile Group, LLC, and other investors

Gritstone Oncology, Inc Announces Resignation of Jean-Marc Bellemin as Chief Financial Officer

New 90-day high: €2.82

Third quarter 2020 earnings released: US$0.69 loss per share

Revenue misses expectations

Gritstone Oncology, Inc. Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE

Gritstone Oncology, Inc.(NasdaqGS:GRTS) dropped from S&P Global BMI Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken